Eli Lilly’s oral GLP-1 agonist orforglipron won FDA approval for adults with obesity or overweight with weight-related conditions, branded Foundayo. Lilly’s therapy is positioned to enter the U.S. market ahead of Novo Nordisk’s oral Wegovy launch timeline and intensify the head-to-head contest for oral uptake. Novo Nordisk responded with public claims about Wegovy’s relative weight-loss performance and noted dosing and usage differences—fueling a debate that will likely be decided by real-world prescribing patterns, insurer access, and head-to-head evidence. Separate reporting also highlighted pricing and policy dynamics tied to federal actions and health-system distribution models that could determine near-term market share for oral incretin competitors.